Detail akcie Rezolute Rg online

Business Summary: Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Financial Summary: BRIEF: For the three months ended 30 September 2025, Rezolute Inc revenues was not reported. Net loss increased 18% to $18.2M. Higher net loss reflects General and administrative - Balancing increase of 52% to $5.3M (expense), Stock-based Compensation in SGA increase of 98% to $1.4M (expense), Stock-based Compensation in R&D increase of 64% to $1.2M (expense).